20 completed, 7 recruiting, 6 unknown, 4 not yet recruiting. 12 Phase 2, 10 Phase 3, 6 Not applicable, 3 Phase 1, 2 Phase 4.
Follow Arthritis, Gouty: new trials by email Literature Review of Arthritis, Gouty trials Research Report on Arthritis, Gouty
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout Pharmacist-Led - Gout, Gouty Arthritis | Not applicable | Recruiting | VA Office of Research and Development | 310 | 2026-10-01 | 2026-10-21 |
| A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W - Gout Arthritis | Phase 2 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 200 | 2026-08-02 | 2026-07-20 |
| Musculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis Rheumatoid Arthritis (RA), Gouty Arthritis (GA) | Not yet recruiting | Assiut University | 100 | 2026-07-01 | 2026-06-18 | |
| Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity Digital Care Community Common Good Program, Usual Care - Type2Diabetes, Hypertension | Not applicable | Recruiting | Chang Gung University of Science and Technology | 169 | 2026-05-12 | 2026-08-21 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| An Exploratory Clinical Study on the Protective Effect of Cycling on the Ankle Joint in Gout Urate-lowering therapy (ULT), Jogging, Cycling - Gout Arthritis, Cycling | Not applicable | Not yet recruiting | Zhu Xiaoxia | 90 | 2026-01-01 | 2025-12-31 |
| Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares Purified Cortophin Gel, 40 U, Purified Cortophin Gel 80 U - Gout Arthritis, Gout Flare | Phase 4 | Recruiting | Massachusetts General Hospital | 150 | 2025-12-20 | 2026-01-20 |
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients AR882 75 mg, XOI Low Dose, XOI High Dose - Gout, Gouty Arthritis | Phase 2 | Active not recruiting | Arthrosi Therapeutics | 15 | 2025-12-03 | 2026-05-15 |
| Nurse-Led Telehealth for Gout Nurse-Led Self-Management Support, GP-follow up - Health Literacy, Gout Arthritis | Not applicable | Recruiting | University of Aarhus | 200 | 2025-10-01 | 2025-09-18 |
| Mass Spectrometry-based Immune Profiling in Autoimmune Diseases Systemic Lupus Erthematosus, Sjogren's Syndrome | Enrolling by invitation | Peking University People's Hospital | 500 | 2025-05-25 | 2026-08-26 | |
| Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy Ex Vivo Assay - Rheumatic Diseases, Rheumatoid Arthritis (RA) | Recruiting | University of Bonn | 120 | 2025-04-01 | 2025-09-02 | |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 866 | 2025-03-11 | 2026-09-28 |
| Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis Etoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose - Gout Arthritis, Gout Attack | Phase 3 | Recruiting | Laboratorios Silanes S.A. de C.V. | 72 | 2025-01-27 | 2025-04-03 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 818 | 2024-06-26 | 2026-10-14 |
| A Bioequivalence Study of Two Different Dosage Form of Genakumab Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection) - Gouty Arthritis (GA) | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 178 | 2024-06-24 | 2025-02-11 |
| A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg, Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, Colchicine 0.5 mg - Gout Arthritis | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 157 | 2024-03-30 | 2024-08-05 |
| A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) dose-5 group, dose-1 group, dose-2 group - Gout Arthritis | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 30 | 2024-03-05 | 2024-03-22 |
| A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis Qingzhu Granules, Qingzhu Granules Placebo - Gouty Arthritis | Phase 3 | Completed | Tasly Pharmaceutical Group Co., Ltd | 472 | 2023-11-07 | 2026-02-27 |
| The MAD Study of SSGJ-613 in Healthy Subjects SSGJ-613, Placebo - Arthritis, Gouty | Phase 1 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 36 | 2023-08-10 | 2023-08-01 |
| NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares Gout Arthritis | Unknown | Centre Hospitalier Saint Joseph Saint Luc de Lyon | 10 | 2023-04-28 | 2023-05-12 |
Showing 20 of 42. Sign in to see all of them.
Gout (17) · Hyperuricemia (10) · Arthritis, Rheumatoid (4) · Arthritis (3) · Osteoarthritis (3) · Arthritis, Psoriatic (2) · Myositis (2) · Pain (2) · Scleroderma, Systemic (2) · Agnosia (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1) · Arthralgia (1) · Autoimmune Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (42) · Crystal Arthropathies (42) · Genetic Diseases, Inborn (42) · Joint Diseases (42) · Metabolic Diseases (42) · Metabolism, Inborn Errors (42) · Musculoskeletal Diseases (42) · Nutritional and Metabolic Diseases (42) · Purine-Pyrimidine Metabolism, Inborn Errors (42) · Rheumatic Diseases (41) · Arthritis (39) · Gout (25) · Pathological Conditions, Signs and Symptoms (14) · Pathologic Processes (12) · Immune System Diseases (6)
canakinumab (6) · Allopurinol (3) · Colchicine (3) · Etoricoxib (2) · Febuxostat (2) · Triamcinolone Acetonide (2) · Betamethasone (1) · Celecoxib (1) · Dexamethasone (1) · Diclofenac (1) · Drug Contamination (1) · Indomethacin (1) · Injections (1) · Jogging (1) · Metformin (1)
Novartis Pharmaceuticals (6) · Arthrosi Therapeutics (5) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · Assiut University (1) · Centre Hospitalier Saint Joseph Saint Luc de Lyon (1) · Centre Hospitalier Universitaire de Nice (1) · Chang Gung University of Science and Technology (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Haiphong University of Medicine and Pharmacy (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Italian Society for Rheumatology (1) · Iuliu Hatieganu University of Medicine and Pharmacy (1) · Laboratorios Silanes S.A. de C.V. (1) · Massachusetts General Hospital (1) · Menoufia University (1)
United States (15) · Taiwan (9) · China (7) · Russia (5) · France (4) · Germany (4) · Spain (4) · Argentina (3) · Australia (3) · Colombia (3) · Poland (3) · Singapore (3) · United Kingdom (3) · Belgium (2) · Canada (2)
Robert Keenan, MD (3) · R Keenan, MD (2) · Charles V Pollack, MD (1) · Debra Diercks, MD (1) · Hejian Zou, MD (1) · Hsiu Ting Tsai, PhD (1) · Hyon K Choi, MD, DrPH (1) · Jia Zhou (1) · Knox Todd, MD (1) · Mikhail Samsonov (1) · Qian Chen, PhD (1)
PMID 21540198, PMID 21849262, PMID 35365187, PMID 36830710, PMID 42582081
I01CX002995 (1)